176 related articles for article (PubMed ID: 37686409)
21. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
23. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
24. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
25. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
26. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape.
Gui C; Wei J; Mo C; Liang Y; Cen J; Chen Y; Wang D; Luo J
Int J Biol Sci; 2023; 19(12):3951-3969. PubMed ID: 37564213
[No Abstract] [Full Text] [Related]
28. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
29. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
30. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
31. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
32. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract][Full Text] [Related]
33. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract][Full Text] [Related]
34. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
[TBL] [Abstract][Full Text] [Related]
36. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
37. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
38. A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients.
Xiao X; Li J; Wan S; Wu M; Li Z; Tian J; Mi J
Front Genet; 2022; 13():1006151. PubMed ID: 36386841
[No Abstract] [Full Text] [Related]
39. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
40. LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.
Zhang X; Tian C; Cheng J; Mao W; Li M; Chen M
Exp Ther Med; 2022 Sep; 24(3):563. PubMed ID: 36034756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
